☆ 3.9 Article

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

EUROPEAN UROLOGY SUPPLEMENTS (2012)

Get Full Text
Add to Collection

Journal

EUROPEAN UROLOGY SUPPLEMENTS
Volume 11, Issue 1, Pages e130-e130a

Publisher

Elsevier BV
DOI: 10.1016/s1569-9056(12)60129-8

Keywords

-

Categories

-

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.